PAR — Paradigm Biopharmaceuticals Balance Sheet
0.000.00%
Last trade - 00:00- AU$120.72m
- AU$96.13m
- AU$6.52m
- 54
- 18
- 84
- 54
Annual balance sheet for Paradigm Biopharmaceuticals, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 105 | 71.1 | 39.7 | 56.4 | 17.9 |
| Net Total Receivables | 3.51 | 8.51 | 6.72 | 6.81 | 5.08 |
| Prepaid Expenses | |||||
| Total Current Assets | 108 | 81 | 47.2 | 63.8 | 24.3 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.943 | 0.764 | 0.571 | 0.336 | 0.19 |
| Net Intangible Assets | |||||
| Other Long Term Assets | |||||
| Total Assets | 112 | 84.8 | 50.7 | 67.1 | 27.4 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 3.36 | 5.79 | 7.83 | 13 | 3.36 |
| Capital Lease Obligations | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 4.18 | 6.52 | 8.38 | 13.4 | 3.58 |
| Common Stock | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 108 | 78.3 | 42.3 | 53.7 | 23.8 |
| Total Liabilities & Shareholders' Equity | 112 | 84.8 | 50.7 | 67.1 | 27.4 |
| Total Common Shares Outstanding |